BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Dec 12, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Cabozantinib: Interim Phase II data

Updated interim data from 44 evaluable patients in the cohort of subjects with metastatic breast cancer in the lead-in stage of an adaptive, international Phase II trial showed that once-daily oral cabozantinib produced 6 partial responses (PR), plus 26 cases of stable disease (SD), with a 12-week disease control rate (DCR) of 48%. In 10 patients with available bone scans at baseline and >=1 post-baseline scan, 4 patients achieved partial resolution of their metastatic bone lesions by week 12. Additionally, 5 of 12 patients with bone metastases and bone pain at...

Read the full 432 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >